Treatment for sulfur mustard lung injuries; New therapeutic approaches from acute to chronic phase

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Poursaleh, Zohreh ^a   Harandi, Ali Amini ^a   Vahedi, Ensieh ^a   Ghanei, Mostafa ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute; Chronic; COPD; Lung; Sulfur mustard; Treatment

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; APROTININ; AZITHROMYCIN; BECLOMETASONE; BUTYLCRESOL; CITRULLINE; CLARITHROMYCIN; CORTICOSTEROID; CURCUMIN; DEXAMETHASONE; DOXYCYCLINE; ERYTHROMYCIN; FLUTICASONE PROPIONATE; GAMMA TOCOPHEROL; GAMMA1B INTERFERON; L THIOCITRULLINE; MANNITOL; METHYLPREDNISOLONE; MUSTARD GAS; N(G) NITROARGININE METHYL ESTER; PREDNISOLONE; ROXITHROMYCIN; SALBUTAMOL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; GASTROESOPHAGEAL REFLUX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG INJURY; NONHUMAN; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION;

EID: 84868331032     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-20-27     Document Type: Review

References (98)

1. Mustard gas toxicity: the acute and chronic pathological effects. Ghabili K, Agutter PS, Ghanei M, Ansarin K, Shoja MM, J Appl Toxicol 2010 30 7 627 643 10.1002/jat.1581 20836142
2. Vesicants. Sidell FR, Urbanetti JS, Smith WJ, Medical Aspects of Chemical and Biological Warfare Washington, DC: Office of the Surgeon General-Department of the Army; United States of America, Zajtchuk R, Bellamy RF, 1997 197 228
3. Vesicant agents. Prentiss AM, Chemicals in warfare: a treatise on chemical warfare New York: USA 1937 177 300
4. Mustard: A potential agent of chemical warfare and terrorism. Saladi RN, Smith E, Persaud AN, Clin Exp Dermatol 2006 31 1 5 10.1111/j.1365-2230.2005. 01945.x 16309468
5. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10years after a single, heavy exposure: analysis of 197 cases. Emad A, Rezaian GR, Chest 1997 112 3 734 738 10.1378/chest.112.3.734 9315808 (Pubitemid 27410711)
6. Medical Notes on the Chemical Warfare: Part II (in persion). Foroutan SA, Kowsar Med J 1997 1 159 177
7. Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography. Ghanei M, Mokhtari M, Mohammad MM, Aslani J, Eur J Radiol 2004 52 2 164 169 10.1016/j.ejrad.2004.03.018 15489074 (Pubitemid 39361117)
8. Battlefield chemical inhalation injury. Urbanetti JS, Pathophysiology and Treatment of Inhalation Injuries New York: Marcel Dekker, Inc, Loke J, 1988 281 348
9. Bronchiolitis obliterans in a survivor of a chemical weapons attack. Thomason JW, Rice TW, Milstone AP, JAMA 2003 290 5 598 599 10.1001/jama.290.5. 598 12902361 (Pubitemid 37430478)
10. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Willemse BW, Postma DS, Timens W, ten Hacken NH, Eur Respir J 2004 23 3 464 476 10.1183/09031936.04.00012704 15065840 (Pubitemid 38344387)
11. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N, Dresler C, et al. Eur Respir J 2008 32 4 844 853 10.1183/09031936.00160007 18827152
12. Molecular and cellular mechanism of lung injuries due to exposure to sulfur mustard: a review. Ghanei M, Harandi AA, Inhal Toxicol 2011 23 7 363 371 10.3109/08958378.2011.576278 21639706
13. Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complication of sulfur mustard poisoning and its correlation with severity of airway diseases. Attaran D, Lari SM, Khajehdaluee M, Ayatollahi H, Towhidi M, Asnaashari A, et al. Hum Exp Toxicol 2009 28 12 739 745 10.1177/0960327109354311 19919970
14. Long term consequences from exposure to sulfur mustard: a review. Ghanei M, Harandi AA, Inhal Toxicol 2007 19 451 456 10.1080/08958370601174990 17365048 (Pubitemid 46364767)
15. Bronchoalveolar lavage fluid proteomic patterns of sulfur mustard-exposed patients. Mehrani H, Ghanei M, Aslani J, Golmanesh L, Proteomics Clin Appl 2009 3 1191 1200 10.1002/prca.200900001 21136943
16. Inflammatory effects of inhaled sulfur mustard in rat lung. Malaviya R, Sunil VR, Cervelli J, Anderson DR, Holmes WW, Conti ML, et al. Toxicol Appl Pharmacol 2010 248 2 89 99 10.1016/j.taap.2010.07.018 20659490
17. Fibrogenic cytokine levels in bronchoalveolar lavage aspirates 15years after exposure to sulfur mustard. Aghanouri R, Ghanei M, Aslani J, Keivani-Amine H, Rastegar F, Karkhaneh A, Am J Physiol Lung Cell Mol Physiol 2004 287 1160 1164 10.1152/ajplung.00169.2003 (Pubitemid 39507192)
18. Bronchiolitis obliterans. Laohaburanakit P, Chan A, Allen RP, Clin Rev Allergy Immunol 2003 25 3 259 274 10.1385/CRIAI:25:3:259 14716071 (Pubitemid 38223544)
19. Bronchiolitis obliterans: an update. Chan A, Allen R, Curr Opin Pulm Med 2004 10 2 133 141 10.1097/00063198-200403000-00008 15021183 (Pubitemid 38402540)
20. Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Ghanei M, Khalili AR, Arab MJ, Mojtahedzadeh M, Aslani J, Lessan-Pezeshki M, et al. Basic Clin Pharmacol Toxicol 2005 97 5 302 305 10.1111/j.1742-7843.2005.pto-187.x 16236142 (Pubitemid 41608123)
21. Biochemical alterations in rat lung lavage fluid following acute sulfur mustard inhalation:II. Increase in proteolytic activity. Cowan FM, Anderson DR, Broomfield CA, Byers SL, Smith WJ, Inhal Toxicol 1997 9 53 61 10.1080/089583797198411 (Pubitemid 27064174)
22. Sferopoulos R, A Review of Chemical Warfare Agent (CWA) Detector Technologies and Commercial-Off-The-Shelf Items 2009 DSTO-GD-0570
23. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Balali-Mood M, Hefazi M, Fundam Clin Pharmacol 2005 19 3 297 315 10.1111/j.1472-8206.2005.00325.x 15910653 (Pubitemid 40769451)
24. Evaluation of protective effects of sodium thiosulfate, cysteine, niacinamide and indomethacin on sulfur mustard-treated isolated perfused porcine skin. Zhang Z, Riviere JE, Monteiro-Riviere NA, Chem Biol Interact 1995 96 3 249 262 10.1016/0009-2797(94)03596-Z 7750164
25. Preferential expression of matrix metalloproteinase-9 in mouse skin after sulfur mustard exposure. Shakarjian MP, Bhatt P, Gordon MK, Chang YC, Casbohm SL, Rudge TL, et al. J Appl Toxicol 2006 26 3 239 246 10.1002/jat.1134 16489579 (Pubitemid 43773884)
26. Clinical management of mustard gas casualties. Willems JL, Ann Med Mil Belg 1989 3 1 61
27. Treatment with dexamethasone or liposome-encapsuled vitamin E provides beneficial effects after chemical-induced lung injury. Wigenstam E, Rocksén D, Ekstrand-Hammarström B, Bucht A, Inhal Toxicol 2009 21 11 958 964 10.1080/08958370802596298 19572781
28. The protective effect of different drugs in rats poisoned by sulfur and nitrogen mustards. Vojvodi V, Milosavljevi Z, Boskovi B, Bojani N, Fundam Appl Toxicol 1985 5 6 Pt 2 160 S168 4092884
29. Oxidants and antioxidants in sulfur mustard-induced injury. Laskin JD, Black AT, Jan Y, Sinko PJ, Heindel ND, Sunil V, et al. Ann N Y Acad Sci 2010 1203 92 100 10.1111/j.1749-6632.2010.05605.x 20716289
30. Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury. Hoesel LM, Flierl MA, Niederbichler AD, Rittirsch D, McClintock SD, Reuben JS, et al. Antioxid Redox Signal 2008 10 5 973 981 18257742 (Pubitemid 351301372)
31. Characterization of the protective effects of L-nitroarginine methyl ester (L-NAME) against the toxicity of sulphur mustard in vitro. Sawyer TW, Toxicology 1998 13 1 21 32 (Pubitemid 28540734)
32. Protection against systemic poisoning by mustard gas, di(2-chloroethyl) sulphide, by sodium thiosulphate and thiocit in the albino rat. Callaway S, Pearce KA, Br J Pharmacol 1958 13 13 395 398
33. Thiosulfate protection against the toxic effects of nitrogen mustard in perfusion of the liver. Foster JH, Lewis MR, Jacobs JK, Am J Surg 1962 28 461 464
34. Protection against the toxicity of all alkylating agents by thiols: the mechanism of protection and its relevance to cancer chemotherapy. Connors TA, Eur J Cancer 1966 2 4 293 305 5342910
35. l-thiocitrulline: A potent protective agent against the toxicity of sulphur mustard in vitro. Sawyer TW, Hancock JR, DAgostino PA, Toxicol Appl Pharmacol 1998 151 2 340 346 10.1006/taap.1998.8457 9707510 (Pubitemid 128421797)
36. The influence of N-acetyl-L-cysteine on oxidative stress and nitric oxide synthesis in stimulated macrophages treated with a mustard gas analogue. Paromov V, Qui M, Yang H, Smith M, Stone WL, BMC Cell Biol. 2008 9 33 10.1186/1471-2121-9-33 18570648 (Pubitemid 352016144)
37. N-Acetylcysteine and Endothelial Cell Injury by Sulfur Mustard. Atkins KB, Lodhi IJ, Hurley LL, Hinshaw DB, J Appl Toxicol 2000 20 1 125 128
38. Butylated hydroxytoluene and N-acetylcysteine attenuates tumor necrosis factor-alpha (TNF-alpha) secretion and TNF-alpha mRNA expression in alveolar macrophages from human lung transplant recipients in vitro. Hultén LM, Lindmark H, Scherstén H, Wiklund O, Nilsson FN, Riise GC, Transplantation 1998 66 3 364 369 15 10.1097/00007890-199808150-00014 9721806 (Pubitemid 28390219)
39. Treatment of sulfur mustard (HD)-induced lung injury. Anderson DR, Byers SL, Vesely KR, J Appl Toxicol 2000 20 Suppl 1 129 S132 11428623
40. Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. Gao X, Ray R, Xiao Y, Ishida K, Ray P, Pulm Pharmacol Ther 2010 23 2 97 106 10.1016/j.pupt.2009.10. 010 19895898
41. Effect of doxycycline on sulfur mustard-induced respiratory lesions in guinea pigs. Guignabert C, Taysee L, Calvet JH, Planus E, Delamanche S, Galiacy S, dOrtho MP, Am J Physiol Cell Mol Physiol 2005 289 67 L74 10.1152/ajplung. 00475.2004 (Pubitemid 40863556)
42. Asthma like symptoms following intratracheal exposure of Guinea pigs to sulfur mustard aerosol: therapeutic efficacy of exogenous lung surfactant curosurf and salbutamol. Van Helden HP, Kuijpers WC, Diemel RV, Inhal Toxicol 2004 16 537e48
43. Doxycycline decreases monocyte chemoattractant protein-1 in human lung epithelial cells. Raza M, Ballering JG, Hayden JM, Robbins RA, Hoyt JC, Exp Lung Res 2006 32 15e26
44. Evaluation of protease inhibitors and an antioxidant for treatment of sulfur mustard-induced toxic lung injury. Anderson DR, Taylor SL, Fetterer DP, Holmes WW, Toxicology 2009 263 41e6
45. Sulfur mustard-induced microvesication in hairless guinea pigs: effect of short-term niacinamide administration. Yourick JJ, Dawson JS, Mitcheltree LW, Toxicol Appl Pharmacol 1992 117 1 104 109 10.1016/0041-008X(92)90223-F 1440603
46. Cysteine esters protect cultured rodent lung slices from sulphur mustard. Wilde PE, Upshall DG, Hum Exp Toxicol 1994 13 11 743 748 10.1177/ 096032719401301102 7857693 (Pubitemid 24351884)
47. Treatment of chemical warfare agents by zero-valent iron nanoparticles and ferrate(VI)/(III) composite. Zboril R, Andrle M, Oplustil F, Machala L, Tucek J, Filip J, Marusak Z, Sharma VK, J Hazard Mater 2012 211-212 126 130 22633883
48. The effect of Nigella sativa alone, and in combination with dexamethasone, on tracheal muscle responsiveness and lung inflammation in sulfur mustard exposed guinea pigs. Boskabady MH, Vahedi N, Amery S, Khakzad MR, J Ethnopharmacol 2011 37 2 1028 1034
49. Treatment with the catalytic metalloporphyrin AEOL 10150 reduces inflammation and oxidative stress due to inhalation of the sulfur mustard analog 2-chloroethyl ethyl sulfide. ONeill HC, White CW, Veress LA, Hendry-Hofer TB, Loader JE, Min E, et al. Free Radic Biol Med 2010 48 9 1188 1196 10.1016/j.freeradbiomed.2010.01.039 20138141
50. Efficacy of concomitant administration of clarithromycin and acetylcysteine in bronchiolitis obliterans in seventeen sulfur mustard exposed patients: An open-label study. Ghanei M, Abolmaali K, Aslani J, Curr Ther Res 2004 6 495 504 (Pubitemid 40332317)
51. N-acetylcysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test. Ghanei M, Shohrati M, Jafari M, Ghaderi S, Alaeddini F, Aslani J, Basic Clin Pharmacol Toxicol 2008 103 5 428 432 10.1111/j.1742-7843.2008.00318.x 18801028
52. Therapeutics effect of N-acetyl cysteine on mustard gas exposed patients: evaluating clinical aspect in patients with impaired pulmonary function test. Shohrati M, Aslani J, Eshraghi M, Alaedini F, Ghanei M, Respir Med 2008 102 443 448 10.1016/j.rmed.2007.10.004 18036807 (Pubitemid 351179975)
53. Airway responses to salbutamol after exposure to chemical warfare. Boskabady MH, Attaran D, Shaffei MN, Respirology 2008 13 2 288 293 10.1111/j.1440-1843.2007.01157.x 18339031 (Pubitemid 351388758)
54. Inhaled corticosteroids and long-acting beta 2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard. Ghanei M, Shohrati M, Harandi AA, Eshraghi M, Aslani J, Alaeddini F, et al. Inhal Toxicol 2007 19 10 889 894 10.1080/08958370701432132 17687719 (Pubitemid 47237745)
55. The therapeutic effect of gamma interferon in chronic bronchiolitis due to mustard gas. Panahi Y, Ghanei M, Aslani J, Mojtahedzadeh M, Iran J Allergy Asthma Immunol 2005 4 2 83 90 17301427
56. Helium:oxygen versus air:oxygen noninvasive positive-pressure ventilation in patients exposed to sulfur mustard. Ghanei M, Rajaeinejad M, Motiei-Langroudi R, Alaeddini F, Aslani J, Heart Lung 2011 40 3 84 e89 10.1016/j.hrtlng.2010.04.001 20561871
57. Mustard gas exposure and carcinogenesis of lung. Hosseini-khalili A, Haines DD, Modirian E, Soroush M, Khateri S, Joshi R, Zendehdel K, Ghanei M, Giardina C, Mutat Res 2009 678 1 1 6 10.1016/j.mrgentox.2009.05.022 19559099
58. Serum levels of IL-8 and IL-6 in the long term pulmonary complications induced by sulfur mustard: Sardasht-Iran Cohort Study. Pourfarzam S, Ghazanfari T, Yaraee R, Ghasemi H, Hassan ZM, Faghihzadeh S, et al. Int Immunopharmacol 2009 9 13-14 1482 1488 19748599
59. Glutathione and malondialdehyde levels in late pulmonary complications of sulfur mustard intoxication. Shohrati M, Ghanei M, Shamspour N, Babaei F, Abadi MN, Jafari M, et al. Lung 2010 188 1 77 83 10.1007/s00408-009-9178-y 19862574
60. Tracheobronchomalacia and air trapping after mustard gas exposure. Ghanei M, Akbari-Moqadam F, Mir-Mohammad M, Aslani J, Am J Respir Crit Care Med 2006 173 3 304 309 10.1164/rccm.200502-247OC 16254272 (Pubitemid 43209085)
61. Increased production of TGF-beta and apoptosis of T lymphocytes isolated from peripheral blood in COPD. Hodge SJ, Hodge GL, Reynolds PN, Scicchitano R, Holmes M, Am J Physiol Lung Cell Mol Physiol 2003 285 492 499
62. Evaluation of chronic cough in chemical chronic bronchitis patients. Ghanei M, Hosseini AR, Arabbaferani Z, Shahkarami E, Environ Toxicol Pharmacol 2005 20 1 6 10 10.1016/j.etap.2004.09.006 21783560 (Pubitemid 40615350)
63. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. N Engl J Med 1999 340 25 1941 1947 10.1056/NEJM199906243402502 10379017 (Pubitemid 29288269)
64. Alterations in serum levels of inflammatory cytokines (TNF, IL-1alpha, IL-1beta and IL-1Ra) 20years after sulfur mustard exposure: Sardasht-Iran cohort study. Yaraee R, Ghazanfari T, Ebtekar M, Ardestani SK, Rezaei A, Kariminia A, et al. Int Immunopharmacol 2009 9 13-14 1466 1470 19747989
65. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ, Am J Respir Crit Care Med 1999 160 1635 1639 10556133
66. Acetylcysteine in the treatment of severe COPD. Dekhuijzen PN, Ned Tijdschr Geneeskd 2006 150 22 1222 1226 3 16796172 (Pubitemid 44011833)
67. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, Reza Khajavi M, Reza Rouini M, Moradi M, et al. Hum Exp Toxicol 2007 26 9 697 703 10.1177/0960327107083452 17984140 (Pubitemid 350157338)
68. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Stav D, Raz M, Chest 2009 136 2 381 386 10.1378/chest.09-0421 19447919
69. Plasma proteomic profile of sulfur mustard exposed lung diseases patients using 2-dimensional gel electrophoresis. Mehrani H, Ghanei M, Aslani J, Tabatabaei Z, Clin Proteomics. 2011 8 1 2 21906349
70. S100 A8: emerging functions and regulation. Passey RJ, Xu K, Hume DA, Geczy CL, J Leukoc Biol 1999 66 549 556 10534107
71. Acute-phase proteins and other systemic responses to inflammation. Gabay C, Kushner I, N Engl J Med 1999 340 448 454 10.1056/NEJM199902113400607 9971870 (Pubitemid 29084777)
72. Late respiratory complications of sulphur mustard. Aslani J, Prevention and treatment of complications of chemical warfare agents Tehran, Iran: Chemical Warfare Research Centre, Cheraghali AM, 2000 76 79
73. Gene expression of profibrotic mediators in bronchiolitis obliterans syndrome after lung transplantation. Bergmann M, Tiroke A, Schäfer H, Barth J, Haverich A, Scand Cardiovasc J 1998 32 97 103 10.1080/14017439850140247 9636965 (Pubitemid 28242924)
74. Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells. Gao X, Ray R, Xiao Y, Barker PE, Ray P, BMC Cell Biol 2007 8 17 10.1186/1471-2121-8- 17 17524151 (Pubitemid 46939417)
75. High prevalence of gastroesophageal reflux symptoms in patients with both acute and nonacute cough. Urita Y, Watanabe T, Ota H, Iwata M, Sasaki Y, Maeda T, et al. Int J Gen Med 2009 1 59 63
76. Review article: respiratory manifestations of gastro-oesophageal reflux disease. Galmiche JP, Zerbib F, Varannes S, Aliment Pharmacol Ther 2008 27 449 464 10.1111/j.1365-2036.2008.03611.x 18194498 (Pubitemid 351300862)
77. Prevalence of upper respiratory symptoms in patients with symptomatic gastroesophageal reflux disease. Theodoropoulos DS, Ledford DK, Lockey RF, Pecoraro DL, Rodriguez JA, Johnson MC, et al. Am J Respir Crit Care Med 2001 164 1 72 76 11435241 (Pubitemid 33151300)
78. Distal esophagitis in patients with mustard-gas induced chronic cough. Ghanei M, Khedmat H, Mardi F, Hosseini A, Dis Esophagus 2006 19 4 285 288 10.1111/j.1442-2050.2006.00580.x 16866862 (Pubitemid 44027093)
79. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. Proc Natl Acad Sci USA 1996 93 14014e9
80. Sulfur mustard-induced pulmonary injury: therapeutic approaches to mitigating toxicity. Weinberger B, Laskin JD, Sunil VR, Sinko PJ, Heck DE, Laskin DL, Pulm Pharmacol Ther 2011 24 1 92 99 10.1016/j.pupt.2010.09.004 20851203
81. Evaluation of activity and phenotype of alpha1-antitrypsin in a civil population with respiratory complications following exposure to sulfur mustard 20years ago. Shohrati M, Shamspour N, Babaei F, Harandi AA, Mohsenifar A, Aslani J, Ghanei M, Biomarkers 2010 15 1 47 51 10.3109/13547500903268318 19788402
82. Effect of gamma interferon on lung function of mustard gas exposed patients, after 15years. Ghanei M, Panahi Y, Mojtahedzadeh M, Khalili AR, Aslani J, Pulm Pharmacol Ther 2006 19 2 148 153 10.1016/j.pupt.2005.07.003 16137903 (Pubitemid 43053003)
83. Angiotensin-converting enzyme genotype and late respiratory complications of mustard gas exposure. Hosseini-Khalili AR, Thompson J, Kehoe A, Hopkinson NS, Khoshbaten A, Soroush MR, et al. BMC Pulm Med 2008 8 15 10.1186/1471-2466-8- 15 18702808
84. A fifty- year mortality follow-up study of veterans exposed to low level chemical warfare agent, mustard gas. Bullman T, Kang H, Ann Epidemiol 2000 10 5 333 338 10.1016/S1047-2797(00)00060-0 10942882 (Pubitemid 30609616)
85. Anti-carcinogenic action of curcumin by activation of antioxidant defence system and inhibition of NF-kappaB signalling in lymphoma-bearing mice. Das L, Vinayak M, Biosci Rep 2012 32 2 161 170 [Research Support, Non-U.S. Govt] 10.1042/BSR20110043 21831045
86. Curcuma as a functional food in the control of cancer and inflammation. Schaffer M, Schaffer PM, Zidan J, Bar Sela G, Curr Opin Clin Nutr Metab Care 2011 14 6 588 597 10.1097/MCO.0b013e32834bfe94 21986478
87. Effects of curcumin on the epithelial mesenchymal transition and TGF-beta/Smads signaling pathway in unilateral ureteral obstruction rats. Li Y, Chen ZQ, Li YD, Zhongguo Zhong Xi Yi Jie He Za Zhi 2011 31 9 1224 1228 22013801
88. Smad molecules expression pattern in human bronchial airway induced by sulfur mustard. Adelipour M, Imani Fooladi AA, Yazdani S, Vahedi E, Ghanei M, Nourani MR, Iran J Allergy Asthma Immunol 2011 10 3 147 154 21891820
89. Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts. Zhang D, Huang C, Yang C, Liu RJ, Wang J, Niu J, et al. Respir Res 2011 12 154 [Research Support, Non-U.S. Govt] 10.1186/1465-9921-12-154 22126332
90. Curcumin regulates airway epithelial cell cytokine responses to the pollutant cadmium. Rennolds J, Malireddy S, Hassan F, Tridandapani S, Parinandi N, Boyaka PN, et al. Biochem Biophys Res Commun 2012 417 1 256 261. 6 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Govt] 10.1016/j.bbrc.2011.11.096 22142850
91. Pharmacokinetics and pharmacodynamics of curcumin. Sharma RA, Steward WP, Gescher AJ, Adv Exp Med Biol. [Review] 2007 595 453 470 10.1007/978-0-387- 46401-5-20
92. When should nebulized hypertonic saline solution be used in the treatment of bronchiolitis? Hom J, Fernandes RM, Paediatr Child Health 2011 16 3 157 158 22379380
93. Sodium channel blockers for cystic fibrosis. Burrows EF, Southern KW, Noone PG, Cochrane Database Syst Rev 2012 3 CD005087
94. The Direct Effect of Hyperosmolar Agents on Ciliary Beating of Human Bronchial Epithelial Cells. Yaghi A, Zaman A, Dolovich MB, J Aerosol Med Pulm Drug Deliv 2012
95. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Reeves EP, Williamson M, ONeill SJ, Greally P, McElvaney NG, Am J Respir Crit Care Med 2011 183 11 1517 1523 10.1164/rccm.201101-0072OC 21330456
96. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. Al-Ansari K, Sakran M, Davidson BL, El Sayyed R, Mahjoub H, Ibrahim K, J Pediatr 2010 157 4 630 634 4 e1 10.1016/j.jpeds.2010.04. 074 20646715
97. Inhaled mannitol for the treatment of cystic fibrosis. Hurt K, Bilton D, Expert Rev Respir Med 2012 6 1 19 26 10.1586/ers.11.87 22283575
98. Airway inflammation and mannitol challenge test in COPD. de Nijs SB, Fens N, Lutter R, Dijkers E, Krouwels FH, Smids-Dierdorp BS, et al. Respir Res 2011 12 11 10.1186/1465-9921-12-11 21241520